- Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2-overexpressing breast cancer: A phase I Dose-Escalation study
[作者:Modi, S; Stopeck, AT; Gordon, MS; Mendelson, D; Solit, DB; Bagatell, R; Ma, W; Wheler, J; Rosen, N; Norton, L; Cropp, GF; Johnson, RG; Hannah, AL; Hudis, CA,期刊:Journal of clinical oncology, 页码:5410-5417 , 文章类型: Article,,卷期:2007年25-34]
- Purpose This phase I study examined whether a heat shock protein (Hsp) 90 inhibitor tanespimycin (17-AAG; KOS-953) could be administered safely in combination with trastuzumab at a dose that inhibits Hsp90 function in vi...
- Symptom prevalence, intensity, and distress in patients with inoperable lung cancer in relation to time of death
[作者:Tishelman, C; Petersson, LM; Degner, LF; Sprangers, MAG,期刊:Journal of clinical oncology, 页码:5381-5389 , 文章类型: Article,,卷期:2007年25-34]
- Purpose To examine symptom prevalence, intensity, and association with distress in patients with inoperable lung cancer (LC), using time to death as point of reference.Patients and Methods A consecutive sample of 400 pat...
- Quantitative justification of the change from 10 % to 30 % for human epidermal growth factor receptor 2 scoring in the American society of clinical Oncology/College of American pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue Microarray based assessment of outcome
[作者:Moeder, CB; Giltnane, JM; Harigopal, M; Molinaro, A; Robinson, A; Gelmon, K; Huntsman, D; Camp, RL; Rimm, DL,期刊:Journal of clinical oncology, 页码:5418-5425 , 文章类型: Article,,卷期:2007年25-34]
- Purpose The variability in scoring of immunohistochemistry, whether a result of true heterogeneity or artifacts in preparation, has led to decreased reliability in companion diagnostics and the recommendation for new sta...
- p53 gene and protein status: The role of p53 alterations in predicting outcome in patients with bladder cancer
[作者:George, B; Datar, RH; Wu, L; Cai, J; Patten, N; Beil, SJ; Groshen, S; Stein, J; Skinner, D; Jones, PA; Cote, RJ,期刊:Journal of clinical oncology, 页码:5352-5358 , 文章类型: Article,,卷期:2007年25-34]
- Purpose The p53 gene status (mutation) and protein alterations (nuclear accumulation detectable by immunohistochemistry; p53 protein status) are associated with bladder cancer progression. Substantial discordance is docu...
- Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption
[作者:Scope, A; Agero, ALC; Dusza, SW; Myskowski, PL; Lieb, JA; Saltz, L; Kemeny, NE; Halpern, AC,期刊:Journal of clinical oncology, 页码:5390-5396 , 文章类型: Article,,卷期:2007年25-34]
- Purpose To evaluate the ability of either oral minocycline, topical tazarotene or both, to reduce or prevent cetuximab-related acneiform rash when administered starting on day 1 of cetuximab therapy.Patients and Methods ...
- Characteristics of urologists predict the use of androgen deprivation therapy for prostate cancer
[作者:Shahinian, VB; Kuo, YF; Freeman, JL; Orihuela, E; Goodwin, JS,期刊:Journal of clinical oncology, 页码:5359-5365 , 文章类型: Article,,卷期:2007年25-34]
- Purpose We previously have reported wide variations among urologists in the use of androgen deprivation for prostate cancer. Using the Surveillance, Epidemiology, and End Results - Medicare linked database, we examined h...
- Phase II study of uracil-tegafur with leucovorin in elderly (>= 75 years old) patients with colorectal cancer: ECOG 1299
[作者:Hochster, HS; Luo, WX; Popa, EC; Lyman, BT; Mulcahy, M; Beatty, PA; Benson, AB,期刊:Journal of clinical oncology, 页码:5397-5402 , 文章类型: Article,,卷期:2007年25-34]
- Purpose To evaluate the tolerability and effectiveness of uracil-tegafur (UFT) with leucovorin (LV) in the treatment of elderly patients with advanced colorectal cancer.Patients and Methods Patients >= 75 years of age wi...
- Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01
[作者:Pommier, P; Chabaud, S; Lagrange, JL; Richaud, P; Lesaunier, F; Le Prise, E; Wagner, JP; Hay, MH; Beckendorf, V; du Chatelard, PMP; Bernier, V; Voirin, N; Perol, D; Carrie, C,期刊:Journal of clinical oncology, 页码:5366-5373 , 文章类型: Article,,卷期:2007年25-34]
- Purpose To assess the benefit and toxicity and quality-of-life (QOL) outcomes of pelvic nodes irradiation in nonmetastatic prostate carcinoma patients.Patients and Methods Between December 1998 and June 2004, 444 patient...
- Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy
[作者:Basch, E; Iasonos, A; Barz, A; Culkin, A; Kris, MG; Artz, D; Fearn, P; Speakman, J; Farquhar, R; Scher, HI; McCabe, M; Schrag, D,期刊:Journal of clinical oncology, 页码:5374-5380 , 文章类型: Article,,卷期:2007年25-34]
- Purpose In cancer treatment trials, clinicians traditionally report patient toxicity symptoms. Alternatively, patients could provide this information directly.Patients and Methods The Common Terminology Criteria for Adve...
- Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of life
[作者:Buijs, C; Rodenhuis, S; Seynaeve, CM; van Hoesel, QGCM; van der Wall, E; Smit, WJM; Nooij, MA; Voest, E; Hupperets, P; TenVergert, EM; van Tinteren, H; Willemse, PHB; Mourits, MJE; Aaronson, NK; Post, WJ; de Vries, EGE,期刊:Journal of clinical oncology, 页码:5403-5409 , 文章类型: Article,,卷期:2007年25-34]
- Purpose To evaluate and compare health-related quality of life (HRQOL) after conventional- and high-dose adjuvant chemotherapy in patients with high-risk breast cancer.Patients and Methods Patients were randomly assigned...
- VCAP-AMP-VECP compared with biweekly CHOP for adult T-Cell leukemia-lymphoma: Japan clinical oncology group study JCOG9801
[作者:Tsukasaki, K; Utsunomiya, A; Fukuda, H; Shibata, T; Fukushima, T; Takatsuka, Y; Ikeda, S; Masuda, M; Nagoshi, H; Ueda, R; Tamura, K; Sano, M; Momita, S; Yamaguchi, K; Kawano, F; Hanada, S; Tobinai, K; Shimoyama, M; Hotta, T; Tomonaga, M,期刊:Journal of clinical oncology, 页码:5458-5464 , 文章类型: Article,,卷期:2007年25-34]
- Purpose Our previous phase II trial for treating human T-lymphotropic virus type I-associated adult T-cell leukemia-lymphoma (ATLL) with vincristine, cyclophosphamide, doxorubicin, and prednisone (VCAP), doxorubicin, ran...
- Cancer care Ontario and American society of clinical oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non-small-cell lung cancer guideline
[作者:Pisters, KMW; Evans, WK; Azzoli, CG; Kris, MG; Smith, CA; Desch, CE; Somerfield, MR; Brouwers, MC; Darling, G; Ellis, PM; Gaspar, LE; Pass, HI; Spigel, DR; Strawn, JR; Ung, YC; Shepherd, FA,期刊:Journal of clinical oncology, 页码:5506-5518 , 文章类型: Article,,卷期:2007年25-34]
- Purpose To determine the role of adjuvant chemotherapy and radiation therapy in patients with completely resected stage IA-IIIA non-small-cell lung cancer (NSCLC).Methods The Cancer Care Ontario Program in Evidence-Based...
|